Nuformix (LON:NFX) Shares Down 0.5% – What’s Next?

Shares of Nuformix plc (LON:NFX) traded down 0.5% during trading on Wednesday . The stock traded as low as GBX 0.16 and last traded at GBX 0.18. 43,758,137 shares were traded during mid-day trading, an increase of 15% from the average session volume of 38,127,719 shares. The stock had previously closed at GBX 0.19.

Nuformix Stock Down 0.5%

The company’s 50 day moving average is GBX 0.18 and its 200 day moving average is GBX 0.23. The firm has a market capitalization of £4.80 million, a price-to-earnings ratio of -4.68 and a beta of 1.55.

Nuformix (LON:NFX) last posted its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.